Australian pharma giant Althea Group Holdings Limited (ASX:AGH) in an ASX announcement on 18 November 2020, shared that Germany’s health department has now granted all needed licenses for selling and distributing Althea products in Germany.
Althea, reportedly, shall be the first Australia company to supply made in Australia medicinal cannabis extract products to be sold in Germany.
December 2020 might even see the first order of 2000 Althea products to be delivered to AGH’s distribution partner Nimbus Health GmbH in Germany.
Germany, with a population of around 83 million, reportedly, has a great market for cannabis and therefore, is a vital opportunity for Althea.
Meanwhile, the AGH stock was seen trading up by 2.127% at $0.480 per share with a market capitalisation of $112.76 million at 02:17 PM AEDT.